Abhay Joshi
2019
In 2019, Abhay Joshi earned a total compensation of $1.9M as Chief Operating Officer at Revance Therapeutics, a 15% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $204,211 |
|---|---|
| Option Awards | $939,314 |
| Salary | $485,479 |
| Stock Awards | $271,373 |
| Other | $9,520 |
| Total | $1,909,897 |
Joshi received $939.3K in option awards, accounting for 49% of the total pay in 2019.
Joshi also received $204.2K in non-equity incentive plan, $485.5K in salary, $271.4K in stock awards and $9.5K in other compensation.
Rankings
In 2019, Abhay Joshi's compensation ranked 6,180th out of 13,971 executives tracked by ExecPay. In other words, Joshi earned more than 55.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,180 out of 13,971 | 56th |
Division Manufacturing | 2,321 out of 5,701 | 59th |
Major group Chemicals And Allied Products | 845 out of 2,200 | 62nd |
Industry group Drugs | 713 out of 1,886 | 62nd |
Industry Pharmaceutical Preparations | 528 out of 1,398 | 62nd |
Source: SEC filing on March 26, 2020.
Joshi's colleagues
We found five more compensation records of executives who worked with Abhay Joshi at Revance Therapeutics in 2019.
2019
Mark Foley
Revance Therapeutics
Chief Executive Officer
2019
L Browne
Revance Therapeutics
Chief Executive Officer
2019
Caryn McDowell
Revance Therapeutics
General Counsel
2019
Tobin Schilke
Revance Therapeutics
Chief Financial Officer
2019
Dustin Sjuts
Revance Therapeutics
Chief Commercial Officer
News
Revance Therapeutics CEO Mark Foley's 2021 pay slips 19% to $7.1M
March 24, 2022
Revance Therapeutics CEO Mark Foley's 2020 pay falls 49% to $8.8M
March 11, 2021
Revance Therapeutics CEO Mark Foley receives $17M in 2019
March 26, 2020
Revance Therapeutics CEO L Browne's 2018 pay jumps 37% to $4.7M
March 25, 2019